BPC-157: what the research says.
Last updated May 30, 2026
A short synthetic peptide studied in animal models for tissue repair and recovery. Interest is real; regulatory status is clear. Here’s what the evidence supports, what it doesn’t, and what the current legal picture is.
Regulatory notice: BPC-157 is currently classified as an FDA Category 2 bulk drug substance. As of April 2026, licensed compounding pharmacies are not legally permitted to prepare or dispense it. BPC-157 is not offered by PepScribe. This page is for educational purposes only and does not constitute medical advice or an offer to sell any product.
On February 27, 2026, the U.S. Department of Health and Human Services announced an intent to reclassify certain peptides, potentially including BPC-157. This announcement has not been formally published in the Federal Register and carries no legal effect until it is. Do not interpret this page as confirmation that BPC-157’s legal status has changed or that PepScribe will offer it in the future.
What BPC-157 is.
BPC-157, “body protection compound”, is a 15-amino-acid synthetic peptide corresponding to a fragment of a larger protein isolated from human gastric juice. It was first described in the early 1990s by Predrag Sikiric and colleagues at the University of Zagreb, and the same research group has produced the majority of the published literature on it across the three decades since.
Unlike most peptides that mimic a single hormone or bind a single receptor, BPC-157 appears to operate through multiple biological pathways, modulation of growth-factor signaling (VEGF, EGF, bFGF), nitric-oxide pathway effects, and interactions with the dopaminergic and serotonergic systems. No single receptor has been established as the primary target; the literature describes it as broadly cytoprotective. It is also unusual in showing activity via both injection and oral administration in animal models, which is uncommon for peptide compounds.
Proposed mechanisms.
Four pathways recur across the preclinical literature. None are confirmed in large-scale, independent human trials.
Blood-vessel formation
Sikiric et al. (2006, Journal of Physiology Paris) demonstrated that BPC-157 promotes new blood-vessel formation in damaged tissue in rat models. The effect was mediated through VEGF upregulation, potentially improving nutrient delivery to repair sites.
Receptor upregulation
Sikiric et al. (2014, Current Pharmaceutical Design) reported that BPC-157 may upregulate growth-hormone-receptor expression in animal models. Interaction with the GH/IGF-1 axis remains an active area of investigation.
NO modulation
A series of studies reviewed in 2016 (Current Pharmaceutical Design) showed BPC-157 interacting bidirectionally with the nitric-oxide system in rat models, counteracting both NO-synthase inhibition and excess NO, consistent with a modulatory role on blood-flow and inflammation signaling.
Cytokine modulation
Multiple publications from the Zagreb group (1993–2020s) report anti-inflammatory activity through several pathways, including effects on TNF-α and IL-6 in animal injury models. Exact mechanisms are still being characterized.
These mechanisms are based on preclinical and animal research, primarily from a single research group. None have been confirmed through large-scale, independent human trials.
The research landscape.
The published BPC-157 evidence base is dominated by animal studies, the bulk of them from the Sikiric group at the University of Zagreb. Human clinical trial data is limited. Below are the four areas where the preclinical signal is strongest.
Tendon and ligament repair.
Chang et al. (2003, Journal of Orthopaedic Research) found that BPC-157 accelerated tendon-to-bone healing in a rat Achilles tendon model. Krivic et al. (2010, Journal of Orthopaedic Surgery and Research) reported improved tendon-healing outcomes versus controls. Neither finding has been replicated in human trials.
Gastrointestinal mucosal protection.
Given its origin in gastric proteins, BPC-157 has been extensively studied for GI-protective effects. Sikiric et al. published a foundational 1993 paper (Journal of Physiology Paris) showing mucosal protection against ethanol- and NSAID-induced damage in rats. Subsequent work (2012–2020, Current Pharmaceutical Design) extended cytoprotection across several GI injury models.
Muscle injury recovery.
Pevec et al. (2010, Journal of Physiology Paris) reported improved muscle healing in rat crush-injury models treated with BPC-157, with the proposed mechanism involving angiogenesis and growth-factor modulation. A 2019 review (Current Pharmaceutical Design) summarized the preclinical muscle-repair literature; human data is still absent.
Neuroprotective signal.
Preclinical work in Current Neuropharmacology (2018) and Current Pharmaceutical Design (2020) reported neuroprotective effects in animal models of drug-induced neurotoxicity, including protection against dopaminergic damage. This is the earliest-stage area of the BPC-157 literature and is not characterized in humans.
What we know and don’t know.
- Accelerated healing in rodent tendon and GI models
- Effects on growth-factor signaling pathways
- Broad cytoprotective profile across tissue types
- Acceptable short-term safety in animal studies
- Clinical effectiveness in specific human indications
- Optimal human dosing and route of administration
- Long-term human safety
- Comparative effectiveness vs. standard-of-care therapies
Administration in research.
In published research, BPC-157 has been studied via subcutaneous injection and oral capsule administration. Both routes have shown activity in animal models, though bioavailability and optimal dosing have not been established through human pharmacokinetic studies.
Dosing in research contexts varies widely. There is no established human protocol from regulatory-grade clinical trials, and no consensus dose-finding across the preclinical literature.
This is research context, not prescribing guidance. BPC-157 is not offered by PepScribe and the information on this page should not be interpreted as a dosing recommendation.
Side effects and safety.
The honest read: human safety data on BPC-157 is thin. Here’s what exists.
Tolerability in animal models.
In the available preclinical data, BPC-157 has shown a favorable safety profile across a range of doses. Xu et al. (2020, Regulatory Toxicology and Pharmacology) reported that no LD50 could be established in rodents; single-dose rat studies up to 20 mg/kg produced no mortality and no general-signs abnormalities over 14-day follow-up. BPC-157 was also well tolerated in mice, rabbits, and dogs across separate preclinical evaluations.
Limited human data.
There are no large-scale, peer-reviewed human safety trials for BPC-157. Most safety inferences are drawn from animal models and anecdotal reports, an important limitation. A Phase I trial for ulcerative colitis (NCT04465890) was registered on ClinicalTrials.gov, but results have not been published in peer-reviewed literature as of April 2026.
Theoretical considerations.
- Possible interactions with anticoagulants given the angiogenesis and blood-flow effects in animal models.
- Caution in individuals with active cancer, given the pro-angiogenic properties observed preclinically.
- No peptide should be used in pregnancy or while breastfeeding without direct physician guidance.
Educational information; not medical advice. Talk to a licensed clinician before considering any peptide therapy.
Regulatory context.
BPC-157 was placed on the FDA’s Category 2 list of bulk drug substances in September 2023. As of April 2026, licensed compounding pharmacies in the United States cannot legally prepare or dispense it.
On February 27, 2026, the U.S. Department of Health and Human Services announced an intent to reclassify certain peptides, potentially including BPC-157. That announcement has not been formally published in the Federal Register and carries no legal effect until it is.
Gray-market “research chemical” vendors sell substances labeled as BPC-157, but those products are unregulated. Their purity, potency, and identity cannot be verified by consumers, and they carry separate risks unrelated to the compound itself.
Available alternatives
While BPC-157 isn’t available, these are.
Recovery, tissue support, and cellular repair, through legally available, 503A-compounded peptides prescribed by a licensed clinician.
Looking for a clinician-led recovery protocol that doesn’t commit you to a specific peptide up front? Take the assessment and a clinician will recommend the right protocol.
Deep dives
More on BPC-157.
Research-backed articles covering specific topics in depth.
Explore clinician-led alternatives.
BPC-157 is not available. PepScribe's programs route you to therapies that are, with a clinician in the loop.